Amalgamated Bank Trims Position in STAAR Surgical (NASDAQ:STAA)

Amalgamated Bank lessened its stake in shares of STAAR Surgical (NASDAQ:STAA) by 2.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 14,590 shares of the medical instruments supplier’s stock after selling 418 shares during the period. Amalgamated Bank’s holdings in STAAR Surgical were worth $542,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of STAA. Swiss National Bank raised its holdings in shares of STAAR Surgical by 0.8% during the 1st quarter. Swiss National Bank now owns 77,100 shares of the medical instruments supplier’s stock worth $2,951,000 after acquiring an additional 600 shares during the period. Russell Investments Group Ltd. lifted its position in STAAR Surgical by 1.5% in the first quarter. Russell Investments Group Ltd. now owns 36,931 shares of the medical instruments supplier’s stock valued at $1,406,000 after buying an additional 555 shares during the last quarter. ProShare Advisors LLC lifted its position in STAAR Surgical by 8.4% in the first quarter. ProShare Advisors LLC now owns 9,892 shares of the medical instruments supplier’s stock valued at $379,000 after buying an additional 763 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in STAAR Surgical by 11.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 15,441 shares of the medical instruments supplier’s stock valued at $591,000 after buying an additional 1,560 shares during the last quarter. Finally, Covestor Ltd lifted its position in STAAR Surgical by 38.9% in the first quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock valued at $103,000 after buying an additional 754 shares during the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on STAA shares. Canaccord Genuity Group decreased their target price on shares of STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a research report on Friday, November 1st. Stifel Nicolaus decreased their target price on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, August 26th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $43.33.

STAAR Surgical Stock Performance

Shares of STAA opened at $26.66 on Friday. The stock has a market capitalization of $1.31 billion, a PE ratio of 60.59 and a beta of 0.61. STAAR Surgical has a 1 year low of $26.62 and a 1 year high of $52.68. The company’s 50-day simple moving average is $31.29 and its 200-day simple moving average is $37.28.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.